by Paul McIntosh | Jul 14, 2026 | 2026, In the News
NovaBiotics’ cysteamine pipeline continues to advance through its collaboration with the Liverpool School of Tropical Medicine (LSTM). Grant funding from the Medical Research Council has been secured to investigate how cysteamine can boost the immune...
by Paul McIntosh | May 8, 2025 | 2025, Press Releases
Tinexyl® PRO, marketed by NovaBiotics Consumer Health Ltd and developed by the biotechnology company NovaBiotics, is a first-of-its-kind conditioning product for toenails, only available through UK podiatrists and foot health practitioners. Its unique, proprietary...
by Paul McIntosh | Mar 24, 2025 | 2025, Press Releases
On world TB Day 2025, NovaBiotics Ltd (NovaBiotics) and Liverpool School of Tropical Medicine (LSTM) announce that they are working together to investigate the use of oral cysteamine bitartrate in the treatment of mycobacterial disease, including tuberculosis (TB)....
by Paul McIntosh | Jan 28, 2025 | 2025, Press Releases
The Institute of Podiatrists are delighted to announce their endorsement of Tinexyl PRO. Our Medicines and Procedures Panel (MaPP) were invited to assist with the product review of Tinexyl PRO over a year ago. During this time MaPP have played an active role in...
by Paul McIntosh | Nov 20, 2024 | 2024, In the News, Uncategorized
The company and its Research & Development activities to tackle antimicrobial resistance, infectious and respiratory disease was highlighted in a recent report by Healthcare UK, a joint initiative of the Department of Health and Social Care, NHS England and the...
Recent Comments